{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:47:37Z","timestamp":1771627657549,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tokyo Medical University Cancer Research Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jss.2019.12.047","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T18:54:10Z","timestamp":1581101650000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"250","author":[{"given":"Saeko","family":"Teraoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2019.12.047_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1634\/theoncologist.12-2-142","article-title":"BRCA1, a potential predictive biomarker in the treatment of breast cancer","volume":"12","author":"James","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jss.2019.12.047_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(00)80238-5","article-title":"Genetic analysis of BRCA1 function in a defined tumor cell line","volume":"4","author":"Scully","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.jss.2019.12.047_bib3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective Hcc1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2019.12.047_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/onc.2013.85","article-title":"BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling","volume":"33","author":"Sung","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jss.2019.12.047_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cc.5.9.2726","article-title":"BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance","volume":"5","author":"Chabalier","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jss.2019.12.047_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-007-9600-1","article-title":"Hereditary breast cancer consortium. Response to Neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers","volume":"108","author":"Byrski","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2019.12.047_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.26351","article-title":"The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"118","author":"Kriege","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2019.12.047_bib8","first-page":"SC7","article-title":"Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of Brca1 mutations","volume":"14","author":"Wysocki","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jss.2019.12.047_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0117-z","article-title":"Prediction of BRCA1-association in hereditary non-BRCA1\/2 breast carcinomas with array-CGH","volume":"116","author":"Joosse","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2019.12.047_bib10","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/bjc.2013.144","article-title":"Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers","volume":"108","author":"Lips","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2019.12.047_bib11","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/bcr3049","article-title":"Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness","volume":"13","author":"Lips","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jss.2019.12.047_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An ACGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jss.2019.12.047_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2019.06.003","article-title":"Anthracycline could be essential for triple-negative breast cancer: a randomised phase ii study by the Kanagawa breast oncology group (Kbog) 1101","volume":"47","author":"Narui","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.jss.2019.12.047_bib14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ejso.2016.02.246","article-title":"BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane","volume":"42","author":"Ishikawa","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2019.12.047_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2325\/jbcs.13.38","article-title":"Issues in the assessment of the pathologic effect of primary systemic Therapy for breast cancer","volume":"13","author":"Kuroi","year":"2006","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jss.2019.12.047_bib16","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2019.12.047_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of brca1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jss.2019.12.047_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-017-4624-7","article-title":"Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1\/2 mutation-associated breast cancer","volume":"168","author":"Telli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2019.12.047_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the Tnt trial","volume":"05","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jss.2019.12.047_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jss.2019.12.047_bib21","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr3655","article-title":"Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy","volume":"16","author":"Vollebergh","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jss.2019.12.047_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042030041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042030041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:48:03Z","timestamp":1758379683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002248042030041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":22,"alternative-id":["S002248042030041X"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2019.12.047","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2019.12.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}